XML 48 R26.htm IDEA: XBRL DOCUMENT
v3.20.4

Major Customers, Partnerships and Strategic Alliances (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Kite Pharma, Inc. ("Kite") |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues recognized under agreement | Revenues recognized under the agreement were as follows (in thousands):
| Year Ended December 31,
| 2020 |  | 2019 |  | 2018 |  |  |
Revenue related to Kite agreement: |  |  |  |  |  |  |  |
Recognition of license and stand-ready fee | $ | 25,046 |  |  | $ | 24,977 |  |  | $ | 18,545 |  |  |  |
Research services | 3,562 |  |  | 9,373 |  |  | 6,972 |  |  |  |
Total | $ | 28,608 |  |  | $ | 34,350 |  |  | $ | 25,517 |  |  |  |
Pfizer, Giroctocogene Fitelparvovec |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues recognized under agreement | Revenues recognized under the agreement were as follows (in thousands):
| Year Ended December 31,
| 2020 |  | 2019 |  | 2018 |  |
Revenue related to Pfizer giroctocogene fitelparvovec agreement: |  |  |  |  |  |  |
Recognition of upfront fee and research services | $ | 3,111 |  |  | $ | 15,697 |  |  | $ | 37,810 |  |  |
Milestone achievement | 31,338 |  |  | 23,662 |  |  | — |  |  |
Total | $ | 34,449 |  |  | $ | 39,359 |  |  | $ | 37,810 |  |  |
Pfizer C9ORF72 |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues recognized under agreement | Revenues recognized under the agreement were as follows (in thousands):
| Year Ended December 31,
| 2020 |  | 2019 |  | 2018 |  |
Revenue related to Pfizer C9ORF72 agreement: |  |  |  |  |  |  |
Recognition of upfront fee | $ | 7,985 |  |  | $ | 1,827 |  |  | $ | 2,188 |  |  |
Milestone achievement | 5,000 |  |  | — |  |  | — |  |  |
Total | $ | 12,985 |  |  | $ | 1,827 |  |  | $ | 2,188 |  |  |
During the year ended December 31, 2020, the Company recorded adjustments to revenue related to changes in estimate in connection with the C9ORF72 collaboration agreement with Pfizer. These adjustments were a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. These adjustments increased revenue by $8.8 million, decreased net loss by $8.8 million and decreased the Company’s basic net loss per share by $0.06 for the year ended December 31, 2020.
Sanofi |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues recognized under agreement | Revenues recognized under the agreement were as follows (in thousands):
| Year Ended December 31,
| 2020 |  | 2019 |  | 2018
Revenue related to Sanofi agreement: |  |  |  |  |
Recognition of upfront fee | $ | 298 |  |  | $ | 3,494 |  |  | $ | 4,013 |
Research services | 4,823 |  |  | 6,367 |  |  | 9,503 |
Milestone achievement | 201 |  |  | 12,819 |  |  | — |
Total | $ | 5,322 |  |  | $ | 22,680 |  |  | $ | 13,516 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |